Literature DB >> 25348330

Becker muscular dystrophy severity is linked to the structure of dystrophin.

Aurélie Nicolas1, Céline Raguénès-Nicol1, Rabah Ben Yaou2, Sarah Ameziane-Le Hir1, Angélique Chéron1, Véronique Vié3, Mireille Claustres4, France Leturcq5, Olivier Delalande1, Jean-François Hubert1, Sylvie Tuffery-Giraud6, Emmanuel Giudice1, Elisabeth Le Rumeur7.   

Abstract

In-frame exon deletions of the Duchenne muscular dystrophy (DMD) gene produce internally truncated proteins that typically lead to Becker muscular dystrophy (BMD), a milder allelic disorder of DMD. We hypothesized that differences in the structure of mutant dystrophin may be responsible for the clinical heterogeneity observed in Becker patients and we studied four prevalent in-frame exon deletions, i.e. Δ45-47, Δ45-48, Δ45-49 and Δ45-51. Molecular homology modelling revealed that the proteins corresponding to deletions Δ45-48 and Δ45-51 displayed a similar structure (hybrid repeat) than the wild-type dystrophin, whereas deletions Δ45-47 and Δ45-49 lead to proteins with an unrelated structure (fractional repeat). All four proteins in vitro expressed in a fragment encoding repeats 16-21 were folded in α-helices and remained highly stable. Refolding dynamics were slowed and molecular surface hydrophobicity were higher in fractional repeat containing Δ45-47 and Δ45-49 deletions compared with hybrid repeat containing Δ45-48 and Δ45-51 deletions. By retrospectively collecting data for a series of French BMD patients, we showed that the age of dilated cardiomyopathy (DCM) onset was delayed by 11 and 14 years in Δ45-48 and Δ45-49 compared with Δ45-47 patients, respectively. A clear trend toward earlier wheelchair dependency (minimum of 11 years) was also observed in Δ45-47 and Δ45-49 patients compared with Δ45-48 patients. Muscle dystrophin levels were moderately reduced in most patients without clear correlation with the deletion type. Disease progression in BMD patients appears to be dependent on the deletion itself and associated with a specific structure of dystrophin at the deletion site.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25348330     DOI: 10.1093/hmg/ddu537

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  28 in total

1.  Gene Editing for Duchenne Muscular Dystrophy Using the CRISPR/Cas9 Technology: The Importance of Fine-tuning the Approach.

Authors:  Jacques P Tremblay; Jean-Paul Iyombe-Engembe; Benjamin Duchêne; Dominique L Ouellet
Journal:  Mol Ther       Date:  2016-11       Impact factor: 11.454

2.  CRISPR-Induced Deletion with SaCas9 Restores Dystrophin Expression in Dystrophic Models In Vitro and In Vivo.

Authors:  Benjamin L Duchêne; Khadija Cherif; Jean-Paul Iyombe-Engembe; Antoine Guyon; Joel Rousseau; Dominique L Ouellet; Xavier Barbeau; Patrick Lague; Jacques P Tremblay
Journal:  Mol Ther       Date:  2018-08-16       Impact factor: 11.454

Review 3.  Porcine models of muscular dystrophy.

Authors:  Joshua T Selsby; Jason W Ross; Dan Nonneman; Katrin Hollinger
Journal:  ILAR J       Date:  2015

Review 4.  Dystrophin and the two related genetic diseases, Duchenne and Becker muscular dystrophies.

Authors:  Elisabeth Le Rumeur
Journal:  Bosn J Basic Med Sci       Date:  2015-07-20       Impact factor: 3.363

5.  Structural Basis of Neuronal Nitric-oxide Synthase Interaction with Dystrophin Repeats 16 and 17.

Authors:  Anne-Elisabeth Molza; Khushdeep Mangat; Elisabeth Le Rumeur; Jean-François Hubert; Nick Menhart; Olivier Delalande
Journal:  J Biol Chem       Date:  2015-09-16       Impact factor: 5.157

6.  Dystrophin's central domain forms a complex filament that becomes disorganized by in-frame deletions.

Authors:  Olivier Delalande; Anne-Elisabeth Molza; Raphael Dos Santos Morais; Angélique Chéron; Émeline Pollet; Céline Raguenes-Nicol; Christophe Tascon; Emmanuel Giudice; Marine Guilbaud; Aurélie Nicolas; Arnaud Bondon; France Leturcq; Nicolas Férey; Marc Baaden; Javier Perez; Pierre Roblin; France Piétri-Rouxel; Jean-François Hubert; Mirjam Czjzek; Elisabeth Le Rumeur
Journal:  J Biol Chem       Date:  2018-03-13       Impact factor: 5.157

7.  Exons 45-55 Skipping Using Mutation-Tailored Cocktails of Antisense Morpholinos in the DMD Gene.

Authors:  Yusuke Echigoya; Kenji Rowel Q Lim; Dyanna Melo; Bo Bao; Nhu Trieu; Yoshitaka Mizobe; Rika Maruyama; Kamel Mamchaoui; Jun Tanihata; Yoshitsugu Aoki; Shin'ichi Takeda; Vincent Mouly; William Duddy; Toshifumi Yokota
Journal:  Mol Ther       Date:  2019-07-26       Impact factor: 11.454

8.  Diagnostic Accuracy of Phenotype Classification in Duchenne and Becker Muscular Dystrophy Using Medical Record Data1.

Authors:  Jennifer G Andrews; Molly M Lamb; Kristin Conway; Natalie Street; Christina Westfield; Emma Ciafaloni; Dennis Matthews; Christopher Cunniff; Shree Pandya; Deborah J Fox
Journal:  J Neuromuscul Dis       Date:  2018

9.  Genotype-phenotype correlation in Becker muscular dystrophy in Chinese patients.

Authors:  Ruiyi Yuan; Junfei Yi; Zhiying Xie; Yimeng Zheng; Miao Han; Yue Hou; Zhaoxia Wang; Yun Yuan
Journal:  J Hum Genet       Date:  2018-07-05       Impact factor: 3.172

Review 10.  Moving towards successful exon-skipping therapy for Duchenne muscular dystrophy.

Authors:  Akinori Nakamura
Journal:  J Hum Genet       Date:  2017-06-01       Impact factor: 3.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.